Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Evaluation of primary and secondary molecular disorders determinig drug resistance from a group of proteasome inhibitors (bortezomib, carfilzomib) and other anti myeloma drugs in patients with multiple myeloma

2016/23/B/NZ5/02529

Keywords:

multiple myeloma resistance molecular basis

Descriptors:

  • NZ5_5: Diagnostics in human diseases
  • NZ5_7: Human disease treatment
  • NZ5_9: Other related subjects

Panel:

NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)

Host institution :

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

woj. łódzkie

Other projects carried out by the institution 

Principal investigator (from the host institution):

prof. Tadeusz Robak 

Number of co-investigators in the project: 4

Call: OPUS 12 - announced on 2016-09-15

Amount awarded: 1 015 564 PLN

Project start date (Y-m-d): 2017-10-01

Project end date (Y-m-d): 2021-12-31

Project duration:: 51 months (the same as in the proposal)

Project status: Project settled

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (7)
  • Book publications / chapters in book publications (1)
  1. Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
    Authors:
    Paweł Robak, Edyta Węgłowska, Izabela Dróżdż, Damian Mikulski , Dariusz Jarych, Magdalena Ferlińska, Ewa Wawrzyniak, Małgorzata Misiewicz, Piotr Smolewski , Wojciech Fendler, Janusz Szemraj, and Tadeusz Robak
    Academic press:
    Mediators of Inflammation (rok: 2020, tom: 45449, strony: 1835836), Wydawca: Hindawi
    Status:
    Published
    DOI:
    10.1155/2020/1835836 - link to the publication
  2. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
    Authors:
    Robak P, Jarych D, Mikulski D, Dróżdż I, Węgłowska E, Kotkowska A, Misiewicz M, Smolewski P, Stawiski K, Fendler W, Szemraj J, Robak T
    Academic press:
    Cancers (rok: 2021, tom: 13(5), strony: 951-968), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers13050951 - link to the publication
  3. Bortezomib for the treatment of hematologic malignancies: 15 years later
    Authors:
    Pawel Robak, Tadeusz Robak
    Academic press:
    Expert Opin Investig Drugs. (rok: 2019, tom: 19, strony: 73-92), Wydawca: Taylor & Francis Group
    Status:
    Published
    DOI:
    10.1007/s40268-019-0269-9 - link to the publication
  4. The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
    Authors:
    Paweł Robak , Izabela Drozdz , Dariusz Jarych, Damian Mikulski, Edyta Wegłowska, Monika Siemieniuk-Rys, Małgorzata Misiewicz, Konrad Stawiski, Wojciech Fendler, Janusz Szemraj, Piotr Smolewski and Tadeusz Robak
    Academic press:
    Cancers (rok: 2020, tom: 12, strony: 45340), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers12092569 - link to the publication
  5. Drug resistance in multiple myeloma.
    Authors:
    Robak P, Drozdz I, Szemraj J, Robak T.
    Academic press:
    Cancer Treat Rev (rok: 2018, tom: 70, strony: 199-208), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.ctrv.2018.09.001 - link to the publication
  6. Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
    Authors:
    Robak P, Szemraj J, Mikulski D, Drozdz I, Juszczak K, Jarych D, Misiewicz M, Kościelny K, Fendler W, Robak T
    Academic press:
    J Clin Med (rok: 2021, tom: 10(21), strony: 5028-5040), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/jcm10215028. - link to the publication
  7. Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
    Authors:
    Mikulski D, Robak P, Perdas E, Węgłowska E, Łosiewicz A, Dróżdż I, Jarych D, Misiewicz M, Szemraj J, Fendler W, Robak T
    Academic press:
    J Clin Med (rok: 2021, tom: 11(1), strony: 112-126), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/jcm11010112 - link to the publication
  1. Novel drugs for multiple myeloma
    Authors:
    Pawel Robak, Tadeusz Robak
    Book:
    Topics in Anti-Cancer Research (rok: 2019, tom: 8, strony: 15707), Wydawca: eurekaselect
    Status:
    Published

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy